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THE ANTAGONIST 14, 15 EPOXYEICOSA-5(Z)-ENOIC ACID HAS 
VASODILATOR PROPERTIES IN MESENTERIC VESSELS 
LOUISE S. HARRINGTON, JOHN R. FALCK AND JANE A. MITCHELL 
Unit of Critical Care Medicine, The National Heart and Lung Institute, Imperial 
College, Dovehouse Street, London, SW3 6LY, UK. 
There is now overwhelming evidence for Epoxyeicosatrienoic acids (EETs) as 
endothelial derived hyperpolarising factor (EDHF). Most recently, a number of 
pharmacological tools have been developed for the study of EETs in relation to 
EDHF responses. EETs have been shown to cause relaxation by activating smooth 
muscle large conductance Ca2+ sensitive K+ (BKCa) (Archer et al, 2003). This 
dilatory response has been shown to be specifically inhibited by its analogue 14, 15-
epoxyeicosa-5 (Z) enoic acid (14, 15 EEZE) in both human internal mammary 
artery and bovine coronary artery (Archer et al, 2003). Here we have investigated 
the antagonist effects of 14, 15 EEZE in murine arteries. 
Male Black 6 mice (12-18 weeks) were killed by lethal exposure to CO2. First order 
arteries were isolated and mounted in wire myographs immersed in physiological 
salt solution (PSS). Arteries were equilibrated (30 mins) and tensions normalised as 
described previously (Mulvany and Halpern, 1977). Arteries incubated for 30 
minutes with or without 3µg/ml 14, 15 EEZE. A concentration response curve to 
11, 12 EET was performed cumulatively on arteries pre-contracted with EC80 
U46619. In some experiments, arteries were pre-contracted with EC80 U46619, 
and concentration response to 14, 15 EEZE performed cumulatively.  
 
 
 
 
 
 
 
 
 
 
Figure 1: Vasodilatory effects of 11, 12 EET is inhibited by pre-incubation with 14, 
15 EEZE. Figure 2: Vasodilatory effects of 14, 15 EEZE in U46619 pre-contracted 
arteries. Data is shown as % of U46619 induced tone.  
11, 12 EET is an effective vasodilator of murine mesenteric arteries (figure 1), 
which can be inhibited by the CYP epoxygenase antagonist 14, 15 EEZE. However, 
14, 15 EEZE is an effective vasodilator (figure 2) in U46619 pre-contracted 
arteries.  
We have not identified the mechanism by which 14, 15 EEZE induced vasodilation. 
However, the possibility exists that it is a partial agonist for the EET/EDHF 
receptor. These results illustrate an important pharmacological property of these 
antagonists, which is being increasingly used to study the nature of EDHF. 
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